Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

Michael J. Elman, Neil M Bressler, Haijing Qin, Roy W. Beck, Frederick L. Ferris, Scott M. Friedman, Adam R. Glassman, Ingrid U. Scott, Cynthia R. Stockdale, Jennifer K. Sun

Research output: Contribution to journalArticle

Abstract

Objective: To report expanded 2-year follow-up of a previously reported randomized trial evaluating intravitreal 0.5 mg ranibizumab or 4 mg triamcinolone combined with focal/grid laser compared with focal/grid laser alone for treatment of diabetic macular edema (DME). Design: Multicenter, randomized clinical trial. Participants: A total of 854 study eyes of 691 participants with visual acuity of 20/32 to 20/320 (approximate Snellen equivalent) and DME involving the fovea. Methods: Continuation of procedures previously reported for the randomized trial. Main Outcome: Measures Best-corrected visual acuity and safety at the 2-year visit. Results: At the 2-year visit, compared with the sham + prompt laser group, the mean change in the visual acuity letter score from baseline was 3.7 letters greater in the ranibizumab + prompt laser group (95% confidence interval adjusted for multiple comparisons [aCI], -0.4 to +7.7), 5.8 letters greater in the ranibizumab + deferred laser group (95% aCI, +1.9 to +9.8), and 1.5 letters worse in the triamcinolone + prompt laser group (95% aCI, -5.5 to +2.4). After the 1- to 2-year visit in the ranibizumab + prompt or deferred laser groups, the median numbers of injections were 2 and 3 (potential maximum of 13), respectively. At the 2-year visit, the percentages of eyes with central subfield thickness

Original languageEnglish (US)
Pages (from-to)609-614
Number of pages6
JournalOphthalmology
Volume118
Issue number4
DOIs
StatePublished - Apr 2011

Fingerprint

Triamcinolone
Macular Edema
Lasers
Visual Acuity
Ranibizumab
Randomized Controlled Trials
Outcome Assessment (Health Care)
Confidence Intervals
Safety
Injections

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. / Elman, Michael J.; Bressler, Neil M; Qin, Haijing; Beck, Roy W.; Ferris, Frederick L.; Friedman, Scott M.; Glassman, Adam R.; Scott, Ingrid U.; Stockdale, Cynthia R.; Sun, Jennifer K.

In: Ophthalmology, Vol. 118, No. 4, 04.2011, p. 609-614.

Research output: Contribution to journalArticle

Elman, MJ, Bressler, NM, Qin, H, Beck, RW, Ferris, FL, Friedman, SM, Glassman, AR, Scott, IU, Stockdale, CR & Sun, JK 2011, 'Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema', Ophthalmology, vol. 118, no. 4, pp. 609-614. https://doi.org/10.1016/j.ophtha.2010.12.033
Elman, Michael J. ; Bressler, Neil M ; Qin, Haijing ; Beck, Roy W. ; Ferris, Frederick L. ; Friedman, Scott M. ; Glassman, Adam R. ; Scott, Ingrid U. ; Stockdale, Cynthia R. ; Sun, Jennifer K. / Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. In: Ophthalmology. 2011 ; Vol. 118, No. 4. pp. 609-614.
@article{e651399fbd5548e0ac1c4f858d3d4868,
title = "Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema",
abstract = "Objective: To report expanded 2-year follow-up of a previously reported randomized trial evaluating intravitreal 0.5 mg ranibizumab or 4 mg triamcinolone combined with focal/grid laser compared with focal/grid laser alone for treatment of diabetic macular edema (DME). Design: Multicenter, randomized clinical trial. Participants: A total of 854 study eyes of 691 participants with visual acuity of 20/32 to 20/320 (approximate Snellen equivalent) and DME involving the fovea. Methods: Continuation of procedures previously reported for the randomized trial. Main Outcome: Measures Best-corrected visual acuity and safety at the 2-year visit. Results: At the 2-year visit, compared with the sham + prompt laser group, the mean change in the visual acuity letter score from baseline was 3.7 letters greater in the ranibizumab + prompt laser group (95{\%} confidence interval adjusted for multiple comparisons [aCI], -0.4 to +7.7), 5.8 letters greater in the ranibizumab + deferred laser group (95{\%} aCI, +1.9 to +9.8), and 1.5 letters worse in the triamcinolone + prompt laser group (95{\%} aCI, -5.5 to +2.4). After the 1- to 2-year visit in the ranibizumab + prompt or deferred laser groups, the median numbers of injections were 2 and 3 (potential maximum of 13), respectively. At the 2-year visit, the percentages of eyes with central subfield thickness",
author = "Elman, {Michael J.} and Bressler, {Neil M} and Haijing Qin and Beck, {Roy W.} and Ferris, {Frederick L.} and Friedman, {Scott M.} and Glassman, {Adam R.} and Scott, {Ingrid U.} and Stockdale, {Cynthia R.} and Sun, {Jennifer K.}",
year = "2011",
month = "4",
doi = "10.1016/j.ophtha.2010.12.033",
language = "English (US)",
volume = "118",
pages = "609--614",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

AU - Elman, Michael J.

AU - Bressler, Neil M

AU - Qin, Haijing

AU - Beck, Roy W.

AU - Ferris, Frederick L.

AU - Friedman, Scott M.

AU - Glassman, Adam R.

AU - Scott, Ingrid U.

AU - Stockdale, Cynthia R.

AU - Sun, Jennifer K.

PY - 2011/4

Y1 - 2011/4

N2 - Objective: To report expanded 2-year follow-up of a previously reported randomized trial evaluating intravitreal 0.5 mg ranibizumab or 4 mg triamcinolone combined with focal/grid laser compared with focal/grid laser alone for treatment of diabetic macular edema (DME). Design: Multicenter, randomized clinical trial. Participants: A total of 854 study eyes of 691 participants with visual acuity of 20/32 to 20/320 (approximate Snellen equivalent) and DME involving the fovea. Methods: Continuation of procedures previously reported for the randomized trial. Main Outcome: Measures Best-corrected visual acuity and safety at the 2-year visit. Results: At the 2-year visit, compared with the sham + prompt laser group, the mean change in the visual acuity letter score from baseline was 3.7 letters greater in the ranibizumab + prompt laser group (95% confidence interval adjusted for multiple comparisons [aCI], -0.4 to +7.7), 5.8 letters greater in the ranibizumab + deferred laser group (95% aCI, +1.9 to +9.8), and 1.5 letters worse in the triamcinolone + prompt laser group (95% aCI, -5.5 to +2.4). After the 1- to 2-year visit in the ranibizumab + prompt or deferred laser groups, the median numbers of injections were 2 and 3 (potential maximum of 13), respectively. At the 2-year visit, the percentages of eyes with central subfield thickness

AB - Objective: To report expanded 2-year follow-up of a previously reported randomized trial evaluating intravitreal 0.5 mg ranibizumab or 4 mg triamcinolone combined with focal/grid laser compared with focal/grid laser alone for treatment of diabetic macular edema (DME). Design: Multicenter, randomized clinical trial. Participants: A total of 854 study eyes of 691 participants with visual acuity of 20/32 to 20/320 (approximate Snellen equivalent) and DME involving the fovea. Methods: Continuation of procedures previously reported for the randomized trial. Main Outcome: Measures Best-corrected visual acuity and safety at the 2-year visit. Results: At the 2-year visit, compared with the sham + prompt laser group, the mean change in the visual acuity letter score from baseline was 3.7 letters greater in the ranibizumab + prompt laser group (95% confidence interval adjusted for multiple comparisons [aCI], -0.4 to +7.7), 5.8 letters greater in the ranibizumab + deferred laser group (95% aCI, +1.9 to +9.8), and 1.5 letters worse in the triamcinolone + prompt laser group (95% aCI, -5.5 to +2.4). After the 1- to 2-year visit in the ranibizumab + prompt or deferred laser groups, the median numbers of injections were 2 and 3 (potential maximum of 13), respectively. At the 2-year visit, the percentages of eyes with central subfield thickness

UR - http://www.scopus.com/inward/record.url?scp=79953299899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953299899&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2010.12.033

DO - 10.1016/j.ophtha.2010.12.033

M3 - Article

C2 - 21459214

AN - SCOPUS:79953299899

VL - 118

SP - 609

EP - 614

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 4

ER -